Theme park apparel maker Spirit Jersey expands to Central Florida
2025 DBI Seminole County
Join Orlando Business Journal and business leaders from both the private and public sectors for the 2025 Doing Business in Seminole County panel discussion, EXPO, and networking event.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BenQ Australia to Showcase World's First Android 15 Education Display and AI-Powered Teaching Tools at EDUtech 2025
Where Innovation Meets Wellbeing in Education: Redefining Classrooms with AI and Care-Driven Technology SYDNEY, June 6, 2025 /PRNewswire/ -- BenQ is set to lead the conversation at EDUtech 2025, unveiling the world's first Android 15 education display, alongside a portfolio of AI-driven teaching tools and health-conscious classroom technologies. Visit Booth No. 814 on 11-12 June, 2025, at International Convention Centre, Sydney, to experience how BenQ continues to push the boundaries of smart, safe, and healthy education solutions. Under the theme "AI Wow – AI that Supports", BenQ emphasises its commitment to practical innovation: supporting teachers, engaging students, and ensuring lasting value for schools. "BenQ's education technology reflects a core philosophy: to empower teachers, protect students, and deliver lasting value," said Martin Moelle, Managing Director of BenQ Australia. "The launch of the world's first Android 15 education display isn't just a milestone, it's a promise. By extending this upgrade to our existing RP04 customers, we're showing that innovation and after-sales care can go hand-in-hand. With our AI tools and ClassroomCare® features, we're not just preparing for the future, we're building it for schools, today." RP04 Sets Global Milestone with Android 15 Upgrade BenQ will begin offering Android over-the-air (OTA) upgrades for its BenQ Board Pro RP04 series, which becomes the world's first Android 15 education display. What sets this upgrade apart is that it will be rolled out to all existing RP04 customers, reinforcing BenQ's commitment to after-sales service, software longevity, and long-term value. Schools already using the RP04 can expect a major performance boost, no hardware replacement required. AI That Supports: A Human-First Approach As Australian classrooms increasingly integrate AI, BenQ stands at the forefront with a human-first approach. BenQ Boards are designed to act as intelligent teaching companions, easing the workload on educators while enhancing learning outcomes. Features include: Speech Translation – Break language barriers with instant multilingual communication, ideal for Australia's diverse classrooms. EZ Math Calculator – Convert handwritten math into editable digital content for cleaner, more organised teaching materials. AI Lens – Instantly identify plants and insects to enrich science learning and spark student curiosity. These tools are aligned with AI trends in Australian education, including a focus on equity, engagement, and instructional efficiency. With BenQ, AI is about amplifying the impact of educators and enriching the student experience through practical, accessible innovation. View original content to download multimedia: SOURCE BenQ Corporation Inicia sesión para acceder a tu portafolio
Forbes
an hour ago
- Forbes
Amid AI-Fueled Growth, AVGO Stock's Valuation Raises Concern
CANADA - 2025/01/06: In this photo illustration, the Broadcom company logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Broadcom (NASDAQ: AVGO) announced robust results for the second quarter of fiscal 2025 (ending in October), exceeding consensus estimates for both revenue and earnings. The company reported $15.0 billion in revenue, a 20% year-over-year increase, and adjusted earnings of $1.58 per share, up 44% year-over-year. These figures slightly surpassed analyst expectations of $14.97 billion and $1.57, respectively. This growth was primarily fueled by strong demand for Broadcom's AI semiconductor solutions and contributions from VMware. AI revenue alone surged by 46% year-over-year to over $4.4 billion in Q2, driven by robust demand for AI networking. Alongside impressive sales growth, the company's adjusted EBITDA margin significantly expanded by 700 basis points year-over-year, reaching 66.7% in Q2. Broadcom's outlook for Q3 also appears promising, with anticipated sales of $15.8 billion, slightly ahead of the $15.7 billion consensus. The company expects growth in AI semiconductor revenue to accelerate to $5.1 billion in Q3, with an adjusted EBITDA margin of at least 66%. Despite these solid results, AVGO stock saw a 4% decline in after-market trading on Thursday, June 5. This dip can partly be attributed to the stock's already high valuation. The question for investors is whether to buy AVGO stock at its current price of around $250. This is a tricky decision. While the stock appears attractive, its high valuation makes it particularly susceptible to adverse events, leading to potential volatility. Our analysis, which compares AVGO's current valuation to its recent operating performance and financial health, suggests minimal underlying concerns. Broadcom exhibits a very strong operating performance and financial condition across key parameters, including growth, profitability, financial stability, and downturn resilience. However, if you seek upside with less volatility than a single stock, consider the High-Quality portfolio, which has outperformed the S&P 500 and achieved returns greater than 91% since inception. Separately, see – Is Amazon Stock Still A Buy After Its Recent 25% Rally? Going by what you pay per dollar of sales or profit, AVGO stock looks very expensive compared to the broader market. Broadcom's Revenues have grown considerably over recent years. Broadcom's profit margins are much higher than most companies in the Trefis coverage universe. Broadcom's balance sheet looks strong. AVGO stock has fared worse than the benchmark S&P 500 index during some of the recent downturns. While investors have their fingers crossed for a soft landing by the U.S. economy, how bad can things get if there is another recession? Our dashboard How Low Can Stocks Go During A Market Crash captures how key stocks fared during and after the last six market crashes. In summary, Broadcom's performance across the parameters detailed above is as follows: - Growth: Extremely Strong - Profitability: Very Strong - Financial Stability: Strong - Downturn Resilience: Neutral - Overall: Strong Even though the stock has performed strongly in the parameters discussed, its extremely high valuation supports our conclusion that AVGO is a tricky stock to buy. We think investors would likely be better off waiting for a further dip before picking AVGO stock. Notably, the average analyst price estimate of $254 also suggests that the stock does not have significant room for growth. Of course, we could be wrong, and investors may continue to assign even higher valuation multiples to AVGO stock given its position in the AI boom. Sometimes, valuations take a back seat when investors get eager about the outlook. In fact, evaluating valuation contextually is just one of many approaches we take when constructing the Trefis High Quality (HQ) Portfolio. This portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last four years. This is because, as a group, HQ Portfolio stocks have provided better returns with less risk compared to the benchmark index, offering a less volatile investment experience, as evident in the HQ Portfolio's performance metrics.
Yahoo
an hour ago
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation Highlights Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025 Presentation time: 8:15 am CEST as part of the focused oral session Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies Venue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
